Funding for this research was provided by:
National Institutes of Health (R35-GM127070)
WSBS William Miller Fellowship
Article History
Received: 17 June 2020
Accepted: 8 September 2021
First Online: 23 September 2021
Declarations
:
: Not applicable.
: Not applicable.
: CRV has received consulting fees from Flare Therapeutics, Roivant Sciences, and C4 Therapeutics, has served on the scientific advisory board of KSQ Therapeutics, Syros Pharmaceuticals, and Treeline Biosciences, has received research funding from Boehringer-Ingelheim and Treeline Biosciences, and owns a stock option from Treeline Biosciences.